PHASE III OPEN-LABEL, MULTI-CENTRE, RANDOMISED STUDY COMPARING NUC-1031 PLUS CISPLATIN TO GEMCITABINE PLUS CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC BILIARY TRACT CANCER

Registry ID

NUTIDE:121

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

NUCANA PLC

Start date

2020-03-02

Completion date

2022-03-02

Last update

2019-05-23

Conditions

• BILIARY CANCER

Related clinical trials

• PHASE III, RANDOMIZED, OPEN-LABEL, GLOBAL, MULTICENTER STUDY OF RILVEGOSTOMIG OR DURVALUMAB IN COMBINATION WITH CHEMOTHERAPY AS A FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCER (ARTEMIDE-BILIARY02)
• BEAMION PANTUMOR-1: A PHASE II, MULTICENTRE, MULTICOHORT, OPEN LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZONGERTINIB (BI 1810631) FOR THE TREATMENT OF SELECTED HER2-MUTATED OR OVEREXPRESSED/AMPLIFIED SOLID TUMOURS
• "A PHASE 3 RANDOMIZED, DOUBLE BLIND STUDY OF PEMBROLIZUMAB PLUS GEMCITABINE/CISPLATIN VERSUS PLACEBO PLUS GEMCITABINE/CISPLATIN AS FIRST-LINE THERAPY IN PARTICIPANTS WITH ADVANCED AND/OR UNRESECTABLE BILIARY TRACT CARCINOMA.
• A MULTICENTRE, OPEN-LABEL PHASE II STUDY OF NAB-PACLITAXEL IN COMBINATION WITH GEMCITABINE + CISPLATIN AS FIRST LINE TREATMENT IN PATIENTS WITH UNRESECTABLE BILIARY TRACT CANCER

View on source registry